Immunotherapy has revolutionized the treatment of cancers in the last 15 years, demonstrating that a patient's very own immune system can seek and destroy a tumor even in its earlier stages. One of the most exciting findings from this research is the possibility that the immune system responds against non-inherited (spontaneous) mutations in the TP53
Culture Matters: Individuals affected by LFS reported a wide range of experiences with this rare and poorly understood condition. Limited availability of information often contributed to delays and denial in diagnosis. Their accounts highlight critical yet underexplored issues—such as guilt and helplessness—that warrant urgent attention. Future policies should be informed by these perceived needs
Adolescents and young adults (AYAs) reported family communication difficulties related to LFS that negatively affected their emotional well-being. Stress related to LFS and major life changes both contributed to and were worsened by these family challenges. Clinicians can support AYAs with LFS by asking about family communication, responding with empathy, offering resources to help with
This study examined anxiety and depression in mothers of newborns carrying the TP53 p.R337H variant in southern Brazil. Mothers of carriers showed higher anxiety shortly after genetic testing, but anxiety decreased within four months. Depression levels did not significantly change. Ongoing psychological support may be needed for mothers with existing mental health concerns. (2022)
Despite limited empirical evidence on the benefits and risks of TP53 testing in childhood, most parents in this study readily chose testing and identified multiple benefits. The authors conclude that, within the context of a clinical Li-Fraumeni syndrome diagnosis, parents should continue to be offered TP53 testing for their children, receive clear counseling on potential
On November 2, 2010, the National Cancer Institute convened a workshop at the National Institutes of Health in Bethesda, Maryland, bringing together clinicians and scientists, as well as individuals from families with LFS, to review the state of the science, address clinical management issues, stimulate collaborative research, and engage the LFS family community. This
Monograph on Li-Fraumeni syndrome written by Dr. David Malkin and edited by Arnold Levine: In 1969, Li and Fraumeni described a notable cancer predisposition syndrome. Using a classic epidemiological approach, they conducted a retrospective review of 280 medical charts and 418 death certificates of children diagnosed with rhabdomyosarcoma in the U.S. between 1960 and 1964.
By Thierry Soussi The history of p53 and the different interpretations of its role in cells highlight how scientific paradigms can shape research fields. It also provides valuable lessons for young scientists looking for an engaging and impactful research topic. (October 8, 2010)
P.O. Box 6458
Holliston, MA 01746, USA
Phone: 1-833-4MYLFSA (1-833-469-5372)
Email: info@lfsassociation.org
© Copyright 2026 | Li-Fraumeni Syndrome Association | All Rights Reserved | Terms & Conditions | Privacy Policy
